Exemestane
- Generic Name
- Exemestane
- Brand Names
- Aromasin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H24O2
- CAS Number
- 107868-30-4
- Unique Ingredient Identifier
- NY22HMQ4BX
- Background
Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal women. It irreversibly binds to the active site of the enzyme resulting in permanent inhibition.
- Indication
For the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.
- Associated Conditions
- Stage I Breast Cancer, Refractory, advanced Breast cancer
- Associated Therapies
- -
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 198
- Registration Number
- NCT02057133
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-30
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 118
- Registration Number
- NCT02049957
- Locations
- 🇺🇸
Henry Ford Medical Center, Novi, Michigan, United States
🇺🇸Texas Oncology, P.A. - Tyler, Tyler, Texas, United States
🇫🇷Institut Sainte Catherine, Avignon, Vaculuse, France
Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2021-01-20
- Lead Sponsor
- Spanish Breast Cancer Research Group
- Target Recruit Count
- 693
- Registration Number
- NCT02028507
- Locations
- 🇮🇱
Sheba Medical Center, Tel Hashomer, Israel
🇦🇹Universitätsklinik für Innere Medizin III, Salzburg, Austria
🇦🇹Landes-Krankenhaus Steyr, Steyr, Austria
Pet Imaging as a Biomarker in Hormone Refractory postmenopausaL Women
- First Posted Date
- 2014-01-07
- Last Posted Date
- 2023-08-24
- Lead Sponsor
- Jules Bordet Institute
- Target Recruit Count
- 55
- Registration Number
- NCT02028364
- Locations
- 🇧🇪
CHU Ambroise Paré, Mons, Belgium
🇧🇪Cliniques Universtaires Saint-Luc, Bruxelles, Belgium
🇧🇪institut Jules Bordet, Bruxelles, Belgium
Exemestane Plus Everolimus for Hormone-receptor Positive Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-01
- Last Posted Date
- 2014-01-01
- Target Recruit Count
- 35
- Registration Number
- NCT02025712
- Locations
- 🇨🇳
Unimed Medical Institute, Hong Kong, China
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 247
- Registration Number
- NCT02007512
- Locations
- 🇺🇸
Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Investigational Drug Services, Indianapolis, Indiana, United States
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 160
- Registration Number
- NCT01989780
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
Exemestane in Advanced and Recurrent Endometrial Carcinoma
- First Posted Date
- 2013-10-18
- Last Posted Date
- 2013-10-18
- Target Recruit Count
- 52
- Registration Number
- NCT01965080
- Locations
- 🇳🇴
The Norwegian Radium Hospital, Oslo, Norway
Exemestane and Cyclophosphamide for Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-10-16
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 23
- Registration Number
- NCT01963481
- Locations
- 🇺🇸
NYU Cancer Center, New York, New York, United States
BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2013-09-10
- Last Posted Date
- 2019-01-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 90
- Registration Number
- NCT01938846
- Locations
- 🇧🇪
UNIV UZ Gent, Gent, Belgium
🇧🇪Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇮🇹Azienda Ospedaliera di Parma, Parma, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.